![[Adobe Stock]](https://sp-ao.shortpixel.ai/client/to_webp,q_glossy,ret_img,w_750,h_375/https://www.psypost.org/wp-content/uploads/2026/06/medical-psilocybin-mushrooms-750x375.jpg)
A recent study published in Communications Biology suggests that a single dose of psilocybin, the active compound found in magic mushrooms, provides lasting relief from nerve pain and boosts the effectiveness of a common pain medication. The findings indicate that psilocybin might reshape how the brain processes pain. This offers a potential new approach for people whose chronic pain does not respond to standard treatments.
Chronic pain affects millions of people globally and often severely reduces a person’s quality of life. Current medications for nerve pain, known as neuropathic pain, tend to have negative side effects and carry a risk of addiction. In addition, between 30 and 50 percent of people taking standard nerve pain treatments like gabapentin do not experience sufficient pain relief.
A research team from the University of Reading, University College London, and Compass Pathfinder set out to explore alternative options for chronic pain management. They focused on psilocybin, a classic psychedelic substance known to alter perception and cognition. Previous clinical research suggests that psilocybin provides sustained benefits for mood disorders by reorganizing brain networks and resetting maladaptive patterns of neural connectivity.
Chronic pain also involves altered connectivity and structural changes in the brain that develop over time. The authors suspected that psilocybin might help remodel these dysfunctional pain networks by changing their fundamental organization. They designed an experiment to see if the compound could reduce pain on its own. They also wanted to observe if it might improve the performance of gabapentin over an extended period.
To test their ideas, the scientists used 157 adult mice, including both males and females. They induced a chronic pain state using a surgical procedure where they partially cut specific nerves in the hind leg while leaving one intact. This specific physical trauma accurately mimics human nerve injuries from surgery or diabetes and produces similar pain hypersensitivity.
After the mice developed a high sensitivity to pain, the researchers injected them with either a saline solution or synthetic psilocybin. They used two different dose levels to evaluate the biological effects. The animals received either a standard dose of one milligram per kilogram of body weight or a lower dose of 0.3 milligrams per kilogram. The scientists confirmed the drug reached the brain by observing a specific head twitching movement, which acts as a recognized sign of a psychedelic experience in rodents.
The team assessed pain sensitivity using several specialized behavioral tests. They pressed fine, calibrated filaments against the paws of the mice to measure sensitivity to static pressure. They also stroked the paws with a paintbrush to test for dynamic pain sensitivity, which mimics a human condition where light touch becomes painful. In another test, they placed the mice on a cold surface to observe their physical reactions to temperature changes.
To ensure the psilocybin was not simply making the mice too sedated to react to pain, the authors tracked their spontaneous behavior. They placed the mice in an open arena and recorded how much they moved and explored. The scientists found no adverse effects on the animals’ basic motor skills or general activity levels. This indicates the reduced pain responses were genuine and not a result of physical impairment.
The researchers found that a single dose of psilocybin reduced pain sensitivity in both male and female mice. In male mice, this pain-relieving effect lasted up to 28 days after the injection. In female mice, the significant reduction in pain sensitivity lasted for about a week. The compound also reduced signs of physiological stress in the animals, as measured by a decrease in their physical stress responses and an increase in body weight.
The team also explored whether repeated treatments might be beneficial. They administered the lower dose of psilocybin once a week for three consecutive weeks. The scientists noticed that this repeated dosing schedule amplified and extended the pain relief compared to a single dose. This indicates that a low dose regimen might sustain the therapeutic benefits over an even longer timeframe.
To understand how psilocybin exerts these effects, the authors gave some mice a drug called volinanserin before administering the psilocybin. Volinanserin blocks a specific serotonin receptor in the brain known as the serotonin 2A receptor. When this receptor was blocked, the pain-relieving effects of psilocybin were substantially reduced. This provides evidence that activating the serotonin 2A receptor is necessary for the drug to reduce nerve pain.
Interestingly, the team discovered that injecting psilocybin 30 days before the nerve injury surgery failed to prevent the development of pain hypersensitivity. This suggests that the drug does not work as a protective shield against future pain. Instead, it seems to act by remodeling brain networks that have already become dysfunctional. The drug appears to depend on the presence of established maladaptive pain networks to exert its therapeutic effects.
The scientists then tested how psilocybin interacts with gabapentin, a standard medication used globally for human nerve pain. They gave mice gabapentin during the acute window of psilocybin’s direct pain-relieving effects. The combination produced significantly stronger and longer-lasting pain relief than the gabapentin alone. This points to a synergistic effect when both drugs are active in the system at the same time.
In a secondary test, the authors administered gabapentin 55 days after the initial psilocybin injection. By this time, the direct pain-relieving effects of the psilocybin had completely worn off. However, the mice that had previously received psilocybin experienced dramatic and sustained pain relief lasting up to 96 hours after the gabapentin dose. Mice that had only received a saline injection experienced a much shorter and weaker response to the gabapentin.
The researchers suspect this sustained enhancement is linked to structural changes in the brain. They theorize that psilocybin increases the release of specific growth factors, such as brain derived neurotrophic factor, which help brain cells form new connections. This process of forming new connections might create a biological environment that allows conventional painkillers to work much better. The brain’s pain processing networks may be fundamentally altered for weeks after the psychedelic experience.
While these findings offer hope, there are some limitations to consider. Animal models of pain cannot fully capture the complex emotional and psychological aspects of chronic pain experienced by humans. People should not interpret this study to mean that magic mushrooms will automatically cure their nerve pain. Self-medicating with unregulated substances carries risks and is not recommended as a substitute for professional medical care.
The study also observed a difference in how long the pain relief lasted between male and female mice. The authors note that a fuller characterization of these potential sex differences is necessary. Additional studies are needed to determine if the extended duration seen in males applies to other types of pain behavior in females. It remains unknown how these biological sex differences might translate to human patients.
Future research will need to explore exactly how psilocybin creates these long-lasting changes at a cellular level. The scientists plan to investigate if psilocybin can also enhance the effectiveness of other common pain medications, such as morphine and specific antidepressants. Clinical trials in humans will be required to confirm if these drug combinations are safe and effective. If successful, this approach could offer a new way to treat patients living with treatment-resistant nerve pain.
The study, “Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia,” was authored by Tatum Askey, Daniel Allen-Ross, Daniil Luzyanin, Reena Lasrado, Gary Gilmour, Stephen P. Hunt, Francesco Tamagnini, Maqsood Ahmed, Gary J. Stephens, and Maria Maiarú.
